CD44 antibodies

CD44 antibodies

Clone: DB105
DB105 recognizes the CD44 antigen. CD44 is a marker for many types of cancer stem cells (CSC), including breast CSCs that possess higher tumorigenicity and metastatic potential, colorectal, pancreatic, and prostate CSCs. In addition, expression was observed in several cancers as well as on carcinoma cell lines. Here, CD44 plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth. CD44 is also expressed on mesodermal cells, such as hematopoietic, fibroblastic, and glial cells.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD44 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Alternative names

CD44s, EMCR III, H-CAM, Pgp-1

Technical specifications

  • Antigen: CD44
  • Clone: DB105
  • Isotype: mouse IgG1
  • Alternative names of antigen: CD44s, EMCR III, H-CAM, Pgp-1
  • Molecular mass of antigen [kDa]: 79
  • Distribution of antigen: bone marrow, cancer stem cells, CNS cells, endothelial cells, epithelial cells, kidney, leukocytes, lymphocytes, mesenchymal stem cells, myeloid cells, plasma cells, ES and iPS cells, red blood cells, skeletal muscle, skin, T cells
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: FITC
  • Selected references

    1. Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100: 3983-3988
    2. Dalerba, P. et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104: 10158-10163
    3. Li, C. P. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res. 67: 1030-1037
    4. Collins, A. T. et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65: 10946-10951
    5. Aruffo, A. et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313
    6. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
    7. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
    8. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
    9. Patrawala, L. et al. (2006)
      Highly purified CD44
      +
      prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.
      Oncogene 25: 1696-1708
    10. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
    11. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  • Brochures and posters

  • Certificates

    Please follow this
    link
    to download the Certificate of Conformity (CoC) by lot number.
Product options: 1
170-078-029

CD44-FITC

for 50
tests
EUR 275,00